Baker Avenue Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Baker Avenue Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-400	Closed	-$3.01K	–	1732
2023 Q2	$3.01K	Buy	400 +366	+1,076%	+$2.97K	﹤0.01%	915
2023 Q1	$301	Buy	+34	New	+$336	﹤0.01%	1566
2019 Q2	–	Sell	-47,322	Closed	-$742K	–	248
2019 Q1	$742K	Buy	+47,322	New	+$835K	0.06%	154
2017 Q3	–	Sell	-25,655	Closed	-$852K	–	226
2017 Q2	$852K	Buy	+25,655	New	+$794K	0.11%	121

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Baker Avenue Asset Management's TEVA Position: Q3 2023 in Review

Baker Avenue Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2023, closing a stake of 400 shares — an estimated $3.01K sold.

Baker Avenue Asset Management first reported a position in TEVA in Q2 2017 and held it in 4 quarters. The position peaked at $852K in Q2 2017. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

Baker Avenue Asset Management reported no remaining Teva Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Baker Avenue Asset Management sold 400 Teva Pharmaceuticals shares in Q3 2023, an estimated $3.01K.
Baker Avenue Asset Management first reported a position in Teva Pharmaceuticals in Q2 2017 and held it in 4 quarters.
Baker Avenue Asset Management's Teva Pharmaceuticals position peaked at $852K in Q2 2017.
435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on Baker Avenue Asset Management's 13F filing for Q3 2023, filed 15 Nov 2023.